Abstract
The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 405-411 |
| Number of pages | 7 |
| Journal | Current Opinion in Infectious Diseases |
| Volume | 6 |
| Issue number | 3 |
| State | Published - 1993 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Microbiology (medical)
Cite this
Management of infections in neutropenic patients : Advances in therapy and prevention. / Karp, Judith; Merz, W. G.; Dick, J. D.
In: Current Opinion in Infectious Diseases, Vol. 6, No. 3, 1993, p. 405-411.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of infections in neutropenic patients
T2 - Advances in therapy and prevention
AU - Karp, Judith
AU - Merz, W. G.
AU - Dick, J. D.
PY - 1993
Y1 - 1993
N2 - The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.
AB - The principles guiding the empiric antibiotic therapy for fever and infection in the granulocytopenic host have remained constant since they were formulated over two decades ago. In brief, the absence or impairment of a localizing inflammatory response resulting from granulocytopenia, plus lack of rapid diagnostic tests to identify causative organisms, necessitates the prompt implementation of broad-spectrum antibiotics against potential pathogens. Today, however, there are new options due to advances in three major areas: an expanding therapeutic armamentarium in terms of both broad and targeted coverage; an increasing capacity to define the specific drug susceptibility profiles of diverse organisms in a clinically relevant fashion; and the advent of hematopoietic and immune system biomodulators. As a result, the strategies for prevention, diagnosis, and therapy for infections in the granulocytopenic host are continually being refined. We can now begin to tailor our interventions to address the particular infecting pathogens and the specific host characteristics as determined by the pathogenesis of the underlying disease and the defects induced by antitumor therapy.
UR - http://www.scopus.com/inward/record.url?scp=0027231177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027231177&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0027231177
VL - 6
SP - 405
EP - 411
JO - Current Opinion in Infectious Diseases
JF - Current Opinion in Infectious Diseases
SN - 0951-7375
IS - 3
ER -